Oncolytics Biotech® Inc. Announces Positive REOLSYIN® Clinical Trial Data Presented at ASCO Gastrointestinal Cancers

Oncolytics Biotech® Inc. Announces Positive REOLSYIN® Clinical Trial Data 
Presented at ASCO Gastrointestinal Cancers Symposium 
CALGARY, Jan. 28, 2013 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") 
(TSX:ONC, NASDAQ:ONCY) today announced a poster presentation covering positive 
preliminary results from a Phase I study examining the intravenous 
administration of REOLYSIN in combination with FOLFIRI in patients with 
metastatic colorectal cancer (REO 022). The results were presented at the ASCO 
Gastrointestinal Cancers Symposium in San Francisco, CA, which took place from 
January 24-26, 2013. 
The poster presentation, titled: "A Multicenter Phase I Study of Intravenous 
Administration of REOLYSIN in combination with 
Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) in Patients (pts) with 
Oxaliplatin-Refractory/Intolerant KRAS-Mutant Metastatic Colorectal Cancer 
(mCRC)," was authored by Ocean et al. Twenty-one patients were enrolled in the 
study, including nine that were FOLFIRI-naïve. Of the 18 patients evaluable 
for response there was one partial response and nine had stable disease. The 
combined overall progression free survival (PFS) of FOLFIRI-naïve and 
FOLFIRI-failed patients was 7.4 months. The authors concluded that the 
combination of REOLYSIN and FOLFIRI was safe and well tolerated and resulted 
in disease control in the majority of evaluable patients, including patients 
that had previously progressed on Irinotecan. 
"These results are intriguing, particularly with respect to patients who have 
failed prior FOLFIRI treatment," said Dr. Brad Thompson, President and CEO of 
Oncolytics. "This study, in conjunction with an earlier study examining 
REOLYSIN monotherapy in metastatic colorectal patients (REO 013), formed the 
basis for our decision to proceed into a randomized study in colorectal cancer 
(IND 211), which is now enrolling." 
The trial was a 21-patient, single arm dose escalation study designed to 
determine a maximum tolerated dose and dose-limiting toxicities for the 
combination of REOLYSIN and FOLFIRI. Eligible patients included those with 
histologically confirmed cancer of the colon or rectum with Kras mutation and 
measurable disease. They must have progressed on or within 190 after the last 
dose of an oxaliplatin regimen in the metastatic setting, or be intolerant to 
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development 
of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical 
program includes a variety of human trials including a Phase III trial in head 
and neck cancers using REOLYSIN(®), its proprietary formulation of the human 
reovirus. For further information about Oncolytics, please visit: 
This press release contains forward-looking statements within the meaning of 
the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act 
of 1934, as amended, and forward-looking information within the meaning of 
Canadian securities laws. Statements, other than statements of historical 
facts, included in this press release that address activities, events or 
developments that Oncolytics expects or anticipates will or may occur in the 
future, including such things as, the Company's expectations related to the 
Phase I colorectal cancer trial of REOLYSIN in combination with FOLFIRI, and 
the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, 
and other such matters are forward-looking statements and forward-looking 
information and involve known and unknown risks and uncertainties, which could 
cause the Company's actual results to differ materially from those in the 
forward-looking statements and forward-looking information. Such risks and 
uncertainties include, among others, risks related to the statistical 
sufficiency of patient enrollment numbers in separate patient groups, the 
availability of funds and resources to pursue research and development 
projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of 
REOLYSIN outside a controlled test, the success and timely completion of 
clinical studies and trials, the Company's ability to successfully 
commercialize REOLYSIN, uncertainties related to the research and development 
of pharmaceuticals and uncertainties related to the regulatory process. 
Investors should consult the Company's quarterly and annual filings with the 
Canadian and U.S. securities commissions for additional information on risks 
and uncertainties relating to the forward-looking statement and 
forward-looking information. Investors are cautioned against placing undue 
reliance on forward-looking statements and forward-looking information. The 
Company does not undertake to update these forward-looking statements and 
forward-looking information, except as required by applicable laws.  
The Equicom Group Nick Hurst 300 5th Ave. SW, 10th Floor Calgary, Alberta, T2P 
3C4 Tel: 403.218.2835 Fax: 403.218.2830 nhurst@tmxequicom.com  Dian Griesel, 
Inc. Susan Forman 396 West Broadway, 2nd Floor New York, NY 10012 Tel: 
212.825.3210 Fax: 212.825.3229 sforman@dgicomm.com 
SOURCE: Oncolytics Biotech Inc. 
To view this news release in HTML formatting, please use the following URL: 
CO: Oncolytics Biotech Inc.
ST: Alberta
-0- Jan/28/2013 11:30 GMT
Press spacebar to pause and continue. Press esc to stop.